Literature DB >> 20028748

Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis.

Nagato Sato1, Junkichi Koinuma, Masahiro Fujita, Masao Hosokawa, Tomoo Ito, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, Yataro Daigo.   

Abstract

PURPOSE: We attempted to identify novel biomarkers and therapeutic targets for lung and esophageal cancers. EXPERIMENTAL
DESIGN: We screened for genes that were overexpressed in a large proportion of lung and esophageal carcinomas using a cDNA microarray representing 27,648 genes or expressed sequence tags. A gene encoding WDHD1, a WD repeat and high-mobility group box DNA binding protein 1, was selected as a candidate. Tumor tissue microarray containing 267 archival non-small cell lung cancers and 283 esophageal squamous cell carcinomas (ESCC) was used to investigate the clinicopathologic significance of WDHD1 expression. The role of WDHD1 in cancer cell growth and/or survival was examined by small interfering RNA experiments and cell growth assays. The mechanism of WDHD1 activation through its phosphorylation in cancer cells was examined by immunoprecipitation and kinase assays.
RESULTS: Positive WDHD1 immunostaining was associated with a poor prognosis for patients with non-small cell lung cancer (P = 0.0403) as well as ESCC (P = 0.0426). Multivariate analysis indicated it to be an independent prognostic factor for ESCC (P = 0.0104). Suppression of WDHD1 expression with small interfering RNAs effectively suppressed lung and esophageal cancer cell growth. In addition, induction of the exogenous expression of WDHD1 promoted the growth of mammalian cells. AKT1 kinase seemed to phosphorylate and stabilize the WDHD1 protein in cancer cells.
CONCLUSIONS: WDHD1 expression is likely to play an important role in lung and esophageal carcinogenesis as a cell cycle regulator and a downstream molecule in the phosphoinositide 3-kinase/AKT pathway, and that WDHD1 is a candidate biomarker and a promising therapeutic target for cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028748     DOI: 10.1158/1078-0432.CCR-09-1405

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.

Authors:  Yi Zhang; Jing Li; Yuan Zhou; Zhuqing Li; Changmin Peng; Huadong Pei; Wenge Zhu
Journal:  Cancer Res       Date:  2022-09-16       Impact factor: 13.312

2.  Role of WDHD1 in Human Papillomavirus-Mediated Oncogenesis Identified by Transcriptional Profiling of E7-Expressing Cells.

Authors:  Yunying Zhou; Qishu Zhang; Ge Gao; Xiaoli Zhang; Yafei Liu; Shoudao Yuan; Xiaowei Wang; Jason J Chen
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

3.  Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.

Authors:  Yasutaka Yamada; Rika Nishikawa; Mayuko Kato; Atsushi Okato; Takayuki Arai; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2017-12-01       Impact factor: 3.172

4.  Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer.

Authors:  Gouji Toyokawa; Ken Masuda; Yataro Daigo; Hyun-Soo Cho; Masanori Yoshimatsu; Masashi Takawa; Shinya Hayami; Kazuhiro Maejima; Makoto Chino; Helen I Field; David E Neal; Eiju Tsuchiya; Bruce A J Ponder; Yoshihiko Maehara; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Mol Cancer       Date:  2011-05-28       Impact factor: 27.401

5.  WDHD1 modulates the post-transcriptional step of the centromeric silencing pathway.

Authors:  Chia-Ling Hsieh; Chih-Li Lin; Hsuan Liu; Yao-Jen Chang; Chii-Jiun Shih; Chang Zheng Zhong; Sheng-Chung Lee; Bertrand Chin-Ming Tan
Journal:  Nucleic Acids Res       Date:  2011-01-25       Impact factor: 16.971

Review 6.  The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a Downstream Target of PI3K/AKT Pathway.

Authors:  Qingying Xian; Danxia Zhu
Journal:  J Oncol       Date:  2022-04-05       Impact factor: 4.375

7.  Shared susceptibility loci at 2q33 region for lung and esophageal cancers in high-incidence areas of esophageal cancer in northern China.

Authors:  Xue Ke Zhao; Yi Min Mao; Hui Meng; Xin Song; Shou Jia Hu; Shuang Lv; Rang Cheng; Tang Juan Zhang; Xue Na Han; Jing Li Ren; Yi Jun Qi; Li Dong Wang
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

8.  The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer.

Authors:  Lei Wang; Xin Hu; Peng Wang; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2016-09-13

9.  WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer.

Authors:  Ayse Ertay; Huiquan Liu; Dian Liu; Ping Peng; Charlotte Hill; Hua Xiong; David Hancock; Xianglin Yuan; Marcin R Przewloka; Mark Coldwell; Michael Howell; Paul Skipp; Rob M Ewing; Julian Downward; Yihua Wang
Journal:  Cell Death Dis       Date:  2020-11-21       Impact factor: 8.469

10.  Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma.

Authors:  Qing Wang; Chenming Ma; Wolfgang Kemmner
Journal:  BMC Cancer       Date:  2013-03-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.